Business & Finance
Business and Finance
Business and Finance
Mon, July 26, 2010 Rodman & Renshaw Announces Analyst Discussion with PolyMedix, Inc.
NEW YORK--([ BUSINESS WIRE ])--Rodman& Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), a leading full service investment bank for growth companies today announced that on August 4, 2010, Rodman will host an analyst discussion in its media center with Nicholas Landekic, President and Chief Executive Officer, and Bozena Korczak, Ph.D., Vice President, Drug Development, of PolyMedix, Inc.
The event will be hosted by Simos Simeonidis, Ph.D., Managing Director and Senior Biotechnology Analyst, of Rodman & Renshaw, LLC. The topics to be covered will include an update on the companya™s pipeline, which includes PMX-60056 a synthetic, small-molecule designed as an anticoagulant reversing agent and PMX-30063, an antibiotic that mimics natural host defense proteins.
The event will take place at Rodman & Renshawa™s offices (1251 Avenue of the Americas, 20th Floor, New York, NY 10020)at 4:30PM ET on August 4th, 2010. Institutional investors can RSVP to Marta Wypych at [ mwypych@rodm.com ]. This event will also be webcasted live on Rodman TV ([ www.rodm.tv ]). Advance registration is required at least 30 minutes prior to the start of the broadcast. The event can also be accessed via conference line. Investors should contact your sales representative at Rodman & Renshaw for the dial-in information or visit Rodman TV for the archived video - which will be available 24 hours after the completion of the event.
Background of Management:
Nicholas Landekic
Nicholas Landekic is a Founder of PolyMedix, Inc. and has served as its President, Chief Executive Officer and Director since inception in 2002. Mr. Landekic has more than 25 years of pharmaceutical industry experience. Prior to PolyMedix, he was President and Chief Executive Officer of Locus Discovery. Mr. Landekic has also held positions in Corporate/Business Development, Strategic Marketing and Finance at Guilford Pharmaceuticals, Cephalon, Bristol-Myers Squibb and Johnson & Johnson Corporation (McNeil Pharmaceutical). In addition, he has worked in the research laboratories at Mt. Sinai Medical Center. Mr. Landekic received an M.B.A. from the State University of New York at Albany, an M.A. in Biology from Indiana University and a B.S. in Biology from Marist College.
Bozena Korczak, Ph.D.
Bozena Korczak has served as Vice President, Drug Development of PolyMedix, Inc. since November 2007. Dr. Korczak has over 20 years of experience in discovery, pre clinical and clinical research at burgeoning biotechnology organizations. Prior to joining PolyMedix, Dr. Korczak was a Principal at PharmaReach, a private drug development consulting company and Vice President of Research and Development of Cytochroma, Inc., a private biotechnology company. Dr. Korczak served in various positions of increasing responsibility at Glycodesign, Inc., Allelix Biopharmaceutical, Inc. and Mount Sinai Hospital. She is an author of thirty five peer review scientific papers and holds a Ph.D. in biochemistry from the Polish Academy of Science.
About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious acute cardiovascular disorders and infectious diseases. PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, PolyMedix's lead heptagonist compound, is being developed to reverse the anticoagulant activity of both heparin and low molecular weight heparins. PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin. PMX-30063, PolyMedix's lead antibiotic compound, is a small molecule that mimics human host-defense proteins and has a mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. PolyMedix plans to develop this compound for serious systemic Staphylococcal infections, including MRSA. Both PMX-60056 heptagonist and PMX-30063 antibiotic are undergoing clinical testing. PolyMedix also plans to continue the development of its PolyCides(tm), polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit our website at [ www.polymedix.com ].
AboutRodman & Renshaw Capital Group, Inc.
Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.
Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of deal volume of PIPE and RD financing transactions completed every year since 2005.
For more information visit Rodman & Renshaw on the Internet at [ www.rodm.com ].
MEMBER FINRA, SIPC
